All Biomarkers articles
-
NewsCellular atlas of DCIS reveals clues to invasive breast cancer progression
A large-scale single-cell atlas of ductal carcinoma in situ has identified novel stromal structures and microenvironmental features that may help distinguish lesions at risk of progressing to invasive breast cancer.
-
ArticleWhat a protein damage score can, and can’t, tell drug developers
Protein damage could provide a valuable readout for evaluating potential anti-ageing therapies, but reducing complex biological responses to a single score raises important questions about interpretation and validation.
-
ArticleSearching for Alzheimer’s drug targets, one cell at a time
The PsychAD Consortium is using human genetics, single-cell genomics and automated screening to pinpoint potential drug targets for Alzheimer’s disease and investigate their therapeutic potential.
-
NewsAlzheimer’s risk gene CASS4 found to regulate microglial immune response
Researchers at the University of Virginia Health have uncovered a previously unknown role for the Alzheimer’s risk gene CASS4 in controlling microglial activity, suggesting that restoring its function could offer a novel strategy for slowing disease progression.
-
NewsDNA enhancer switch drives androgen receptor breast cancer suppression
A small regulatory DNA element called HRRINT3 has been found to play a critical role in enabling the androgen receptor to suppress cell growth in oestrogen receptor-positive breast cancer, pointing towards new therapeutic strategies for patients with advanced disease.
-
NewsCell reprogramming induces immune structures across seven cancer types
Asgard Therapeutics has shown that its in vivo cell reprogramming platform can reliably induce mature immunogenic tertiary lymphoid structures across seven tumour types.
-
ArticleWhat tissue accumulation can reveal about oligonucleotide safety
Oligonucleotides can remain in tissues long after disappearing from circulation, but does accumulation necessarily indicate toxicity? Dr Tina Rogers examines the evidence needed to interpret preclinical safety findings.
-
NewsYAP/TAZ protein hyperactivity linked to immune evasion via PD-L2 upregulation
Researchers have identified a mechanism by which overactive YAP and TAZ proteins may simultaneously increase cancer cell visibility to the immune system and shield tumours from T-cell attack.
-
ArticleWhy reagent selection belongs inside assay design
High affinity is often a priority when selecting reagents, but does it guarantee better assay performance? Discover why binding kinetics and matrix selectivity matter when developing custom reagents for challenging targets.
-
NewsImmune profiling could help tailor treatment for primary biliary cholangitis
A new review of primary biliary cholangitis reveals how interactions between bile duct epithelial cells and immune populations sustain chronic inflammation, and explores whether mapping individual disease mechanisms could guide more targeted therapies.
-
ArticleEarlier MSA detection could guide alpha-synuclein drug discovery
MSA and Parkinson’s share the same protein pathology, yet MSA progresses far faster. Could earlier detection reveal why and help researchers identify more effective targets for drug discovery?
-
ArticleFinding drug targets through the noise of complex disease
The strongest disease signal may not point to the best drug target. AI could help researchers identify what matters within complex biological networks.
-
NewsExperimental drug reverses paralysis and vision loss in MS mice
A novel inflammasome inhibitor derived from HIV antivirals has reversed established neurological deficits in a preclinical MS model, raising hopes for a restorative approach to a disease where current therapies focus primarily on relapse prevention.
-
ArticleHow protective gene variants are revealing new drug targets
Finding the right drug target remains one of discovery’s biggest challenges. Human genetics is helping researchers strengthen the evidence before committing years of research and investment.
-
ArticleTurning CNS biomarkers into better drug development decisions
Why do promising CNS therapies struggle to translate into patients? Three experts explore how biomarkers can track therapeutic effects, improve patient selection and guide development decisions.
-
WebinarCracking cell dynamics with single-cell proteomics and CRISPR
What can pooled CRISPR screening and protein‑level readouts reveal that transcriptomics alone can’t? Explore how single‑cell genomic perturbations, intracellular protein measurements and surface‑protein profiling expose signalling pathways and clarify antibody specificity.
-
NewsWhole-genome sequencing delivers actionable biomarkers in 73 percent of cancer patients
A large real-world study demonstrates that whole-genome sequencing can identify actionable biomarkers in nearly three-quarters of solid cancer patients.
-
NewsNew malaria mutations linked to resistance against multiple front-line drugs
Whole-genome sequencing of parasites from Ugandan patients has uncovered a cluster of genetic variants linked to reduced susceptibility to multiple front-line malaria treatments, with researchers warning the mutations are spreading rapidly.
-
NewsGLP-1 drug semaglutide extends lifespan and slows ageing in older mice
A new NIH-funded study suggests the GLP-1 receptor agonist semaglutide may slow biological ageing and extend lifespan in older mice, raising the prospect that GLP-1 drugs could one day be developed as broad longevity-enhancing interventions.
-
ArticleWhat makes a human biospecimen fit for purpose in drug discovery
Human biospecimens can bring drug discovery closer to human disease, but their value depends on far more than the sample itself. We explore the factors that determine how much researchers can learn from them.


